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The draft genome sequence of a ristocetin-producing Amycolatopsis strain (sp. MJM2582) isolated in South Korea is reported
here. This strain has a genome of approximately 8.9 Mb containing 7,933 predicted genes, including the ristocetin cluster and 32
additional predicted secondary metabolite biosynthesis clusters.
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Amycolatopsis sp. MJM2582 was isolated from a rhizospheresample from Ami Mountain in Chungcheongnam-do prov-
ince (located in the western part of South Korea) during a screen-
ing for producers of glycopeptide antibiotics and was subse-
quently observed to produce ristocetin (1). Glycopeptides are an
important class of antibiotics that are particularly effective against
Gram-positive bacteria. This family also includes vancomycin, an
antibiotic of last resort which is reserved for the treatment of se-
rious infections that are resistant to other antibiotics, for example,
methicillin-resistant Staphylococcus aureus (MRSA) (2). The sp.
MJM2582 has been shown to produce a number of different ris-
tocetin derivatives, but ristocetin A is the most abundant product
(1). Ristocetin A is a type III glycopeptide antibiotic and possesses
a distinctive branched tetrasaccharide structure. Strain Amycola-
topsis sp. MJM2582 is therefore an alternative natural source of
ristocetin to the original Amycolatopsis lurida isolate, which is the
current commercial producer of ristocetin A (3). Although a toxic
side effect on platelet aggregation led to the discontinuation of
ristocetin A as a antimicrobial (4), the aglycone of ristocetin A has
been found to be free of this undesirable activity and, more signif-
icantly, exhibits improved antimicrobial activity compared with
the parent compound (5). Here, we report the draft sequence of
Amycolatopsis sp. MJM2582, in which we have identified 33 sec-
ondary metabolite biosynthetic clusters, including the ristocetin A
cluster (GenBank accession number KF882511) (1).
The genome of Amycolatopsis sp. MJM2582 was sequenced us-
ing Illumina MiSeq to a coverage depth of 83-fold and then assem-
bled using the GS De Novo Assembler (Newbler software version
2.8). The assembled genome comprised a total of 13 large contigs.
The average size of these large contigs is 687,568 bp, and the largest
contig is 2,111,476 bp in length. The estimated size of the genome
is 8,932,977 bp with an average GC content of 68.84%. The draft
genome sequence was annotated using the Prokaryotic Genome
Annotation Pipeline (PGAP) with GeneMarkS (6, 7), which
predicted 7,933 coding sequence (CDS) regions, 41 pseudogenes,
54 tRNAs, 14 noncoding RNAs (ncRNAs), and a single copy each
of 5S rRNA, 23S rRNA, and 16S rRNA. The 16S rRNA sequence of
Amycolatopsis sp. MJM2582 showed 99% identity to that of A. lu-
rida, the producer of commercial ristocetin, but phylogenic anal-
ysis indicated that A. sp. CMU-PLA03 is actually taxonomically
the most closely related strain to Amycolatopsis sp. MJM2582. An-
tiSMASH (8) was used to predict potential secondary metabolite
synthetic gene clusters. In addition to the 39 open-reading frames
(ORFs) of the ristocetin A cluster, gene clusters predicted to en-
code the production of lantipeptides, NRPS (nonribosomal pep-
tide synthease) compounds, terpenes, type I polyketide antibiot-
ics, bacteriocins, ectoine, and several unknown metabolites were
identified.
Nucleotide sequence accession numbers. The draft genome
sequence of Amycolatopsis sp. MJM2582 has been deposited in the
DDBJ/EMBL/GenBank database under the accession number
JPLW00000000. The version described in this paper is version
JPLW01000000.
ACKNOLWLEDGMENTS
This work was supported by grants from the Royal Society
(516002.K5877/ROG) and the Medical Research Council (G0700141).
Sequencing was performed by the DNA sequencing facility at the De-
partment of Biochemistry, University of Cambridge (http://www.bioc
.cam.ac.uk/dnasequencing).
REFERENCES
1. Truman AW, Kwun MJ, Cheng J, Yang SH, Suh JW, Hong H-J. 2014.
Antibiotic resistance mechanisms inform discovery: identification and
characterization of a novel Amycolatopsis strain producing ristocetin. An-
timicrob. Agents Chemother. 58:5687–5695. http://dx.doi.org/10.1128/
AAC.03349-14.
2. Grundy WE, Sinclair AC, Theriault RJ, Goldstein AW, Rickher CJ,
Warren HB, Jr, Oliver TJ, Sylvester JC. 1957. Ristocetin, microbiologic
properties. Antibiot. Annu. 1956 –1957:687– 692.
3. Sarji KE, Stratton RD, Wagner RH, Brinkhous KM. 1974. Nature of von
Willebrand factor: a new assay and a specific inhibitor. Proc. Natl. Acad. Sci.
U. S. A. 71:2937–2941. http://dx.doi.org/10.1073/pnas.71.8.2937.
4. Pearson H. 2002. “Superbug” hurdles key drug barrier. Nature 418:
469 – 470. http://dx.doi.org/10.1038/418469b.
5. Herrin TR, Thomas AM. June 1984. Ristocetin -aglycon as an antibac-
terial agent. US patent 4,456,593.
crossmark
Genome AnnouncementsSeptember/October 2014 Volume 2 Issue 5 e01091-14 genomea.asm.org 1
6. Angiuoli SV, Gussman A, Klimke W, Cochrane G, Field D, Garrity GM,
Kodira CD, Kyrpides N, Madupu R, Markowitz V, Tatusova T, Thom-
son N, White O. 2008. Toward an online repository of standard operating
procedures (SOPs) for (meta)genomic annotation. Omics 12:137–141.
http://dx.doi.org/10.1089/omi.2008.0017.
7. Lukashin AV, Borodovsky M. 1998. GeneMark.hmm: new solutions for
gene finding. Nucleic Acids Res. 26:1107–1115. http://dx.doi.org/10.1093/
nar/26.4.1107.
8. Blin K, Medema MH, Kazempour D, Fischbach MA, Breitling R, Takano
E, Weber T. 2013. antiSMASH 2.0 —a versatile platform for genome min-
ing of secondary metabolite producers. Nucleic Acids Res. 41:
W204 –W212. http://dx.doi.org/10.1093/nar/gkt449.
Kwun et al.
Genome Announcements2 genomea.asm.org September/October 2014 Volume 2 Issue 5 e01091-14
